Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11205608 | 0.93 | PDE4A (0.74) | RXFP1MAPK1ADORA2BLMNAPDE4A | |
| SCHEMBL10477410 | 0.89 | RXFP1 (0.74) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| SCHEMBL16120975 | 0.87 | ADORA2B (0.88) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| SCHEMBL16120979 | 0.87 | ADORA2B (0.85) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| SCHEMBL660023 | 0.86 | ADORA2B (0.76) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| Hydroxyamine SCHEMBL10853528 | 0.85 | RXFP1 (0.77) | RXFP1MAPK1ADORA2BLMNAPDE4A | |
| SCHEMBL16120982 | 0.85 | ADORA2B (0.85) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| SCHEMBL16120983 | 0.85 | ADORA2B (0.85) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| SCHEMBL16121000 | 0.85 | ADORA2B (0.85) | RXFP1MAPK1ADORA2BLMNAMAPT | |
| SCHEMBL16120999 | 0.85 | ADORA2B (0.85) | RXFP1MAPK1ADORA2BLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108614-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | RXFP1 3119/4885MAPK1 3067/4885ADORA2B 1599/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | RXFP1 1374/4885MAPK1 3852/4885ADORA2B 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.